Archive for the 'J Proteome Res' Category



Related Articles

Introduction to the Food and Drug Administration (FDA) regulatory process.

J Proteome Res. 2005 Jul-Aug;4(4):1110-3

Authors: Hackett JL, Gutman SI

FDA oversight of medical devices, including in vitro diagnostic devices (IVDs or laboratory tests), in the United States was a direct result of the passage of the Medical Device Amendments of 1976. This law introduced a series of general controls for medical devices including registration and listing, requirements for production using good manufacturing practices, and requirements for post-market reporting of device failures. This produced for the first time a menu of laboratory tests on the market, a system to ensure these were produced consistently over time, and a mechanism for FDA to identify problems with device use and to work with companies to ensure corrective action. This law also introduced the requirement for premarket review of new versions of old devices and of fundamentally new medical devices.

PMID: 16083260 [PubMed - indexed for MEDLINE]




About

You are currently browsing the Regulatory Affairs Syndicator weblog archives for the 'J Proteome Res' category.

Longer entries are truncated. Click the headline of an entry to read it in its entirety.

Categories